Praxis spent more, lost more, and ended the three months with roughly three times as much cash.
The June 30 balance was $474.8 million, up from $157.4 million a year earlier. That is a sharply higher cash balance for a clinical-stage biotech. The operating numbers are less tidy: operating loss widened to $96.9 million from $76.1 million, while research and development spending rose 10.2% to $69.4 million.
The cash balance also comes with a larger share count. Diluted shares rose 35.7% to 29.1 million, and diluted EPS improved to negative $2.87 from negative $3.31 even as net loss widened to $83.7 million from $71.1 million. In other words, the per-share arithmetic improved partly because more shares were in the denominator, not because the business became profitable.
The sharper cash signal appears over six months rather than three. Praxis used $163.7 million in operating cash, compared with $107.7 million in the comparable period. The company attributed the latest burn mainly to its net loss, a decrease in accrued expenses, and non-cash charges including stock compensation.
Praxis describes the mechanics of the rising clinical bill plainly:
"Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials."
10-Q, August 6, 2026
The current three-month numbers fit that description. Stock compensation rose 45.5% to $11.3 million, while the company said personnel and clinical spending added to expenses.
The largest disclosed step-up was tied to the Solidus platform and the EMBRAVE program:
"$9.7 million increase in expense related to our Solidus™ platform, driven primarily by a $5.0 million milestone payment due to Ionis Pharmaceuticals Inc., or Ionis, upon completion of our EMBRAVE Part A study, as well as spend for our EMBRAVE3 pivotal clinical trial; $8.2 million increase in personnel-related costs due to increased headcount; and $3.1 million increase in indirect expenses driven primarily by consulting spend to support operations."
10-Q, August 6, 2026
That makes Ionis a specific piece of the spending story, not just a name in the partner ecosystem. The $5.0 million payment was linked to a study milestone, while EMBRAVE3 added ongoing pivotal-trial spending. The filing does not turn that outlay into revenue, and Praxis reported no annual revenue in 2025.
The central tension is therefore concrete: cash expanded sharply, but the cash leaving through operations expanded too. The latest 10-Q also says future viability depends on regulatory approvals and raising additional capital if needed, which puts the balance-sheet figure alongside a business still funding clinical development rather than selling a commercial product.
Praxis's August 6 10-Q reports $474.8 million of cash and $163.7 million of six-month operating cash use.